The BLOC1S6 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the BLOC1S6 gene has been disrupted by CRISPR/Cas9-mediated gene editing. This polyclonal pool provides a loss-of-function model for investigating BLOC1S6-dependent mechanisms in a human lung adenocarcinoma background. The product is supplied as a heterogeneous population of edited cells, enabling studies that do not require clonal homogeneity, such as population-level analyses of lysosome-related organelle biogenesis and endosomal sorting.
Derived from a 58-year-old Caucasian male with lung adenocarcinoma, the A-549 host cell line displays an adherent epithelial morphology and serves as an alveolar basal epithelial model widely employed in lung cancer and respiratory research. A-549 cells retain key features of type II pneumocytes, including the capacity for surfactant production and lamellar body formation, making them particularly relevant for trafficking studies of lysosome-related organelles. Their tumorigenic background further supports oncological investigations into lysosomal dysregulation.
BLOC1S6 encodes a subunit of the biogenesis of lysosome-related organelles complex-1 (BLOC-1), which is transcriptionally regulated by TFEB and MITF. The BLOC-1 complex interacts with the AP-3 adaptor complex and Rab32/Rab38 GTPases to facilitate cargo delivery from endosomes to specialized organelles. BLOC1S6 forms complexes with other BLOC-1 subunits, including SNAPIN, MUTED, and PLDN, and its activity is essential for the trafficking of melanosome proteins such as TYR and TYRP1, as well as lysosomal membrane proteins LAMP1 and LAMP2. Disruption of BLOC1S6 impairs this trafficking, linking its deficiency to Hermansky-Pudlak syndrome type 9.
In A-549 cells, BLOC-1 is critical for the biogenesis of lamellar bodies, the lysosome-related organelles responsible for pulmonary surfactant storage and secretion. Knocking out BLOC1S6 in this model disrupts surfactant protein trafficking and lamellar body morphology, offering a cell-based system to study Hermansky-Pudlak syndrome-associated pulmonary fibrosis. The model also enables exploration of altered lysosomal function in lung cancer, where enhanced lysosomal activity supports tumor proliferation and invasion. Representative assays include western blotting, immunofluorescence for LAMP1 or TGN46, electron microscopy of lamellar bodies, and surfactant protein ELISA.
The BLOC1S6 Knockout A-549 Polyclonal Cells are suited for diverse applications, including disease modeling of Hermansky-Pudlak syndrome, screening of therapies targeting lysosome-related organelle disorders, and mechanistic studies of endosomal-lysosomal trafficking in lung epithelial cells. Researchers can employ lysosomal function assays with Lysotracker, proliferation assays, or migration/invasion assays to assess phenotypic consequences. This knockout model provides a versatile platform for investigating BLOC1S6-dependent pathways in both normal and cancerous lung contexts. For further details or to discuss specific experimental needs, please contact Ascent Research.
